1.
|
Organic sales growth — page 3
|
2.
|
Core EPS and currency-neutral Core EPS — page 4
|
3.
|
Core gross margin and currency-neutral Core gross margin – page 5
|
4.
|
Core operating profit margin and currency-neutral Core operating profit margin — page 5
|
5.
|
Adjusted free cash flow productivity — page 5
|
•
|
Incremental restructuring:
The Company has had and continues to have an ongoing level of restructuring activities. Such activities have resulted in ongoing annual restructuring related charges of approximately $250 - $500 million before tax. In 2012 the Company
began a $10 billion strategic productivity and cost savings initiative that included incremental restructuring activities. In 2017, the Company communicated details of an additional multi-year productivity and cost savings plan. This
results in incremental restructuring charges to accelerate productivity efforts and cost savings. The adjustment to Core earnings includes only the restructuring costs above what we believe are the normal recurring level of restructuring
costs.
|
•
|
Early debt extinguishment charges: In fiscal 2018, the Company recorded after-tax charges of $243 million, due to the early extinguishment of certain long-term debt. These charges represent the difference between the reacquisition price and the par value of the
debt extinguished.
|
•
|
Transitional Impact of U.S. Tax Reform: In December 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the "U.S. Tax Act"). This resulted in a net charge of $602 million for the fiscal
year 2018. The adjustment to Core earnings only includes this transitional impact. It does not include the ongoing impacts of the lower U.S. statutory rate on the respective years’ earnings.
|
•
|
Gain on Dissolution of the PGT Healthcare Partnership: The Company finalized the dissolution of our PGT Healthcare partnership, a venture between the Company and Teva Pharmaceuticals Industries, Ltd (Teva) in the OTC consumer healthcare business, in the quarter ended
September 30, 2018. The transaction was accounted for as a sale of the Teva portion of the PGT business; the Company recognized an after-tax gain on the dissolution of $353 million.
|
•
|
Shave Care Impairment: In
the fourth quarter of fiscal 2019, the company recognized a one-time, non-cash, after-tax charge of $8.0 billion ($8.3 billion before tax) to adjust the carrying values of the Shave Care reporting unit. This was comprised of a before and
after-tax impairment charge of $6.8 billion related to goodwill and an after-tax impairment charge of $1.2 billion ($1.6 billion before tax) to reduce the carrying value of the Gillette indefinite-lived intangible assets.
|
•
|
Anti-dilutive Impacts: The
Shave Care impairment charges caused certain equity instruments that are normally dilutive (and hence normally assumed converted or exercised for the purposes of determining diluted net earnings per share) to be anti-dilutive.
Accordingly, for U.S. GAAP diluted earnings per share, these instruments were not assumed to be concerted or exercised. Specifically, in the fourth quarter and total fiscal 2019, the weighted average outstanding preferred shares were not
included in the diluted weighted average common shares outstanding. Additionally, in the fourth quarter of fiscal 2019, none of our outstanding share-based equity awards were included in the diluted weighted average common shares
outstanding. As a result of the non-GAAP Shave Care impairment adjustment, these instruments are dilutive for non-GAAP earnings per share.
|
Three Months Ended
September 30, 2019 |
Net Sales Growth
|
Foreign Exchange Impact
|
Acquisition &
Divestiture Impact/Other* |
Organic Sales Growth
|
|||
Beauty
|
8%
|
2%
|
-%
|
10%
|
|||
Grooming
|
(2)%
|
2%
|
1%
|
1%
|
|||
Health Care
|
20%
|
2%
|
(13)%
|
9%
|
|||
Fabric Care & Home Care
|
6%
|
1%
|
1%
|
8%
|
|||
Baby, Feminine & Family Care
|
4%
|
1%
|
-%
|
5%
|
|||
Total P&G
|
7%
|
2%
|
(2)%
|
7%
|
Total Company
|
Net Sales Growth
|
Foreign Exchange Impact
|
Acquisition/ Divestiture Impact*
|
Organic Sales Growth
|
Average
|
|||
JAS 2017
|
1%
|
-%
|
-%
|
1%
|
||||
JAS 2018
|
-%
|
3%
|
1%
|
4%
|
2.5%
|
|||
OND 2017
|
3%
|
(1)%
|
-%
|
2%
|
||||
OND 2018
|
-%
|
4%
|
0%
|
4%
|
3%
|
|||
JFM 2018
|
4%
|
(4)%
|
1%
|
1%
|
||||
JFM 2019
|
1%
|
5%
|
(1)%
|
5%
|
3%
|
|||
AMJ 2018
|
3%
|
(2)%
|
-%
|
1%
|
||||
AMJ 2019
|
4%
|
4%
|
(1)%
|
7%
|
4%
|
|||
JAS 2018
|
-%
|
3%
|
1%
|
4%
|
||||
JAS 2019
|
7%
|
2%
|
(2)%
|
7%
|
5.5%
|
Total Company
|
Net Sales Growth
|
Combined Foreign Exchange &
Acquisition/Divestiture Impact/Other*
|
Organic Sales Growth
|
|||
FY 2020 (Estimate)
|
3% to 5%
|
-%
|
+3% to +5%
|
Three Months Ended
September 30 |
|||
2019
|
2018
|
||
Diluted Net Earnings Per Share
|
$1.36
|
$1.22
|
|
Incremental Restructuring
|
0.01
|
0.03
|
|
Gain on Dissolution of PGT Partnership
|
(0.14)
|
||
Rounding
|
0.01
|
||
Core EPS
|
$1.37
|
$1.12
|
|
Percentage change vs. prior period
|
22%
|
||
Currency Impact to Earnings
|
0.02
|
||
Currency-Neutral Core EPS
|
$1.39
|
||
Percentage change vs. prior period Core EPS
|
24%
|
JAS 18
|
JAS 17
|
OND 18
|
OND 17
|
JFM 19
|
JFM 18
|
AMJ 19
|
AMJ 18
|
|
Diluted Net Earnings Per Share from Continuing Operations, attributable to P&G
|
$ 1.22
|
$ 1.06
|
$ 1.22
|
$ 0.93
|
$ 1.04
|
$ 0.95
|
$ (2.12)
|
$ 0.72
|
Incremental Restructuring
|
0.03
|
0.03
|
0.03
|
0.02
|
0.02
|
0.04
|
0.06
|
0.14
|
Early Debt Extinguishment Charges
|
-
|
0.09
|
||||||
Transitional Impact of U.S. Tax Act
|
0.24
|
0.01
|
(0.02)
|
|||||
Gain on Dissolution of PGT Partnership
|
(0.14)
|
|||||||
Shave Care Impairment
|
3.02
|
|||||||
Anti-dilutive Impacts
|
0.14
|
|||||||
Rounding
|
0.01
|
0.01
|
||||||
Core EPS
|
$ 1.12
|
$ 1.09
|
$ 1.25
|
$ 1.19
|
$ 1.06
|
$ 1.00
|
$ 1.10
|
$ 0.94
|
Percentage change vs. prior period
|
3%
|
5%
|
6%
|
17%
|
||||
Currency Impact to Earnings
|
0.09
|
0.09
|
0.09
|
0.08
|
||||
Currency-Neutral Core EPS
|
$ 1.21
|
$ 1.34
|
$ 1.15
|
$ 1.18
|
||||
Percentage change vs. prior period Core EPS
|
11%
|
13%
|
15%
|
26%
|
Total Company
|
Diluted EPS Growth
|
Impact of Incremental
Non-Core Items*
|
Core EPS Growth
|
FY 2020 (Estimate)
|
+225% to +243%
|
(220)% to (233)%
|
+5% to +10%
|
Three Months Ended
September 30 |
||
2019
|
2018
|
|
Gross Margin
|
51.0%
|
49.2%
|
Incremental Restructuring
|
0.3%
|
0.3%
|
Rounding
|
(0.1)%
|
|
Core Gross Margin
|
51.3%
|
49.4%
|
Basis point change vs. prior year Core margin
|
190
|
|
Currency Impact to Margin
|
0.1%
|
|
Currency-Neutral Core Gross Margin
|
51.4%
|
|
Basis point change vs prior year Core margin
|
200
|
Three Months Ended
September 30 |
||
2019
|
2018
|
|
Operating Profit Margin
|
24.1%
|
21.3%
|
Incremental Restructuring
|
0.2%
|
0.4%
|
Core Operating Profit Margin
|
24.3%
|
21.7%
|
Basis point change vs. prior year Core margin
|
260
|
|
Currency Impact Margin
|
-%
|
|
Currency-Neutral Core Operating Profit Margin
|
24.3%
|
|
Basis point change bs. Prior year Core Margin
|
260
|
Operating Cash Flow
|
Capital Spending
|
U.S. Tax Act Payments
|
Adjusted Free Cash Flow
|
Net Earnings
|
Adjusted Free Cash Flow Productivity
|
$4,169
|
$(1,079)
|
$215
|
$3,305
|
$3,617
|
91%
|